Relationship of betatrophin with youth onset type 2 diabetes among Asian Indians

Diabetes Research and Clinical Practice

Volumn 109, Issue 1, 2015, Pages 71-76

  Gokulakrishnan, Kuppan ^a   Manokaran, Kalaivani ^a   Pandey, Gautam Kumar ^a   Amutha, Anandakumar ^a   Ranjani, Harish ^a   Anjana, Ranjit Mohan ^a   Mohan, Viswanathan ^a  

^a MADRAS DIABETES RESEARCH FOUNDATION   (India)

Author keywords

Asians Indians; Betatrophin; Insulin resistance; Type 2 diabetes

Indexed keywords

ANTIHYPERTENSIVE AGENT; BETATROPHIN; GLUTAMATE DECARBOXYLASE; HEMOGLOBIN A1C; MEMBRANE PROTEIN; METFORMIN; ORAL ANTIDIABETIC AGENT; SULFONYLUREA; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; GLYCOSYLATED HEMOGLOBIN; LIPASIN PROTEIN, HUMAN; PEPTIDE HORMONE;

ADULT; ARTICLE; BODY MASS; CONTROLLED STUDY; CORRELATION ANALYSIS; DIASTOLIC BLOOD PRESSURE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLUCOSE TOLERANCE; HEMOGLOBIN BLOOD LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPERTENSION; INDIAN; INSULIN RELEASE; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; ONSET AGE; PROTEIN BLOOD LEVEL; SYSTOLIC BLOOD PRESSURE; WAIST CIRCUMFERENCE; ADOLESCENT; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD; CHILD; DIABETES MELLITUS, TYPE 2; ETHNOLOGY; INDIA; METABOLISM; PANCREAS ISLET BETA CELL; STATISTICS AND NUMERICAL DATA; YOUNG ADULT;

ADOLESCENT; ADULT; AGE OF ONSET; ASIAN CONTINENTAL ANCESTRY GROUP; BIOMARKERS; CHILD; DIABETES MELLITUS, TYPE 2; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INDIA; INSULIN RESISTANCE; INSULIN-SECRETING CELLS; MALE; PEPTIDE HORMONES; YOUNG ADULT;

EID: 84930822838     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2015.04.028     Document Type: Article

References (44)

1. Tuomi T., Santoro N., Caprio S., Cai M., Weng J., Groop L. The many faces of diabetes: a disease with increasing heterogeneity. Lancet 2014, 383:1084-1094.
2. Stratton I.M., Adler A.I., Neil H.A., Matthews D.R., Manley S.E., Cull C.A., et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000, 321:405-412.
3. Michael M.D., Kulkarni R.N., Postic C., Previs S.F., Shulman G.I., Magnuson M.A., et al. Loss of insulin signaling in hepatocytes leads to severe insulin resistance and progressive hepatic dysfunction. Mol Cell 2000, 6:87-97.
4. Seymour P.A., Serup P. Bulking up on beta cells. NEJM 2013, 369:777-779.
5. Yi P., Park J.S., Melton D.A. Betatrophin: a hormone that controls pancreatic β cell proliferation. Cell 2013, 153:747-758.
6. Kulkarni R.N., Mizrachi E.B., Ocana A.G., Stewart A.F. Human ß-cell proliferation and intracellular signaling: driving in the dark without a road map. Diabetes 2012, 61:2205-2213.
7. El Ouaamari A., Kawamori D., Dirice E., Liew C.W., Shadrach J.L., Hu J., et al. Liver-derived systemic factors drive β cell hyperplasia in insulin-resistant states. Cell Rep 2013, 3:401-410.
8. Lickert H. Betatrophin fuels beta cell proliferation: first step toward regenerative therapy?. Cell Metab 2013, 18:5-6.
9. Fenzl A., Itariu B.K., Kosi L., Fritzer-Szekeres M., Kautzky-Willer A., Stulnig T.M., et al. Circulating betatrophin correlates with atherogenic lipid profiles but not with glucose and insulin levels in insulin-resistant individuals. Diabetologia 2014, 57:1204-1208.
10. Fu Z., Berhane F., Fite A., Seyoum B., Abou-Samra A.B., Zhang R. Elevated circulating lipasin/betatrophin in human type 2 diabetes and obesity. Sci Rep 2014, 4:5013.
11. Zhang R. Lipasin, a novel nutritionally-regulated liver enriched factor that regulates serum triglyceride levels. Biochem Biophys Res Commun 2012, 424:786-792.
12. Wang Y., Quagliarini F., Gusarova V., Gromada J., Valenzuela D.M., Cohen J.C., et al. Mice lacking ANGPTL8 (betatrophin) manifest disrupted triglyceride metabolism without impaired glucose homeostasis. Proc Natl Acad Sci U S A 2013, 110:16109-16114.
13. Gungor N., Arslanian S. Progressive beta cell failure in type 2 diabetes mellitus of youth. J Pediatr 2004, 144:656-659.
14. Hillier T.A., Pedula K.L. Complications in young adults with early-onset type 2 diabetes: losing the relative protection of youth. Diabetes Care 2003, 26:2999-3005.
15. Mohan V., Sharp P.S., Cloke H.R., Burrin J.M., Schumer B., Kohner E.M. Serum immunoreactive insulin responses to glucose load in Asian Indian and European type 2 (non-insulin-dependent) diabetic patients and control subjects. Diabetologia 1986, 29:235-237.
16. Anjana R.M., Pradeepa R., Deepa M., Datta M., Sudha V., Unnikrishnan R., et al. Prevalence of diabetes and prediabetes (impaired fasting glucose and/or impaired glucose tolerance) in urban and rural India: phase I results of the Indian Council of Medical Research-INdia DIABetes (ICMR-INDIAB) study. Diabetologia 2011, 54:3022-3027. ICMR-INDIAB Collaborative Study Group.
17. Sonya J., Ranjani H., Pradeepa R., Mohan V. Obesity Reduction and Awareness and Screening of Noncommunicable Diseases through Group Education in children and adolescents (ORANGE): methodology paper (ORANGE-1). J Diabetes Sci Technol 2010, 4:1256-1264.
18. Alberti K.G., Zimmet P.Z. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus, provisional report of a WHO consultation. Diabet Med 1998, 15:539-553.
19. Amutha A., Datta M., Unnikrishnan R., Anjana R.M., Mohan V. Clinical profile and complications of childhood- and adolescent-onset type 2 diabetes seen at a diabetes center in South India. Diabetes Technol Ther 2012, 14:497-504.
20. The Asia Pacific perspective: Redefining obesity and its treatment 2000, 17-21. Regional Office for the Western Pacific of the World Health Organization. World Health Organization, International Association for the Study of Obesity and International Obesity Task Force. Health Communications Australia Pty Limited, Sydney.
21. de Onis M., Onyango A.W., Borghi E., Siyam A., Nishida C., Siekmann J. Development of a WHO growth reference for school-aged children and adolescents. Bull World Health Organ 2007, 85:660-667.
22. World Health Organization (WHO): available from [accessed 23.1.2015]. http://www.who.int/growthref/growthref_who_bull/en/.
23. Matthews D.R., Hosker J.P., Rudenski A.S., Naylor B.A., Treacher D.F., Turner R.C. Homeostasis model assessment: insulin resistance and beta cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28:412-419.
24. Utzschneider K.M., Prigeon R.L., Faulenbach M.V., Tong J., Carr D.B., Boyko E.J., et al. Oral disposition index predicts the development of future diabetes above and beyond fasting and 2-h glucose levels. Diabetes Care 2009, 32:335-341.
25. Bacha F., Gungor N., Arslanian S.A. Measures of beta cell function during the oral glucose tolerance test, liquid mixed-meal test, and hyperglycemic clamp test. J Pediatr 2008, 152:618-621.
26. O'Brien R.M. A caution regarding rules of thumb for variance inflation factors. Qual Quant 2007, 41:673-690.
27. Rubin D.B. Estimating causal effects from large data sets using propensity scores. Ann Intern Med 1997, 127:757-763.
28. D'Agostino R.B. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 1998, 17:2265-2281.
29. Ferrannini E., Mari A. β-cell function in type 2 diabetes. Metabolism 2014, 63:1217-1227.
30. Weiss R., Taksali S.E., Tamborlane W.V., Burgert T.S., Savoye M., Caprio S. Predictors of changes in glucose tolerance status in obese youth. Diabetes Care 2005, 28:902-909.
31. Mohan V., Amutha A., Ranjani H., Unnikrishnan R., Datta M., Anjana R.M., et al. Associations of β-cell function and insulin resistance with youth-onset type 2 diabetes and prediabetes among Asian Indians. Diabetes Technol Ther 2013, 15:315-322.
32. Staimez L.R., Weber M.B., Ranjani H., Ali M.K., Echouffo-Tcheugui J.B., Phillips L.S., et al. Evidence of reduced β-cell function in Asian Indians with mild dysglycemia. Diabetes Care 2013, 36:2772-2778.
33. Gómez-Ambrosi J., Pascual E., Catalán V., Rodríguez A., Ramírez B., Silva C., et al. Circulating betatrophin concentrations are decreased in human obesity and type 2 diabetes. J Clin Endocrinol Metab 2014, 99:E2004-E2009.
34. Ahnfelt-Rønne J., Madsen O.D. Betatrophin: the long awaited circulating factor from the liver promoting β-cell replication?. Islets 2014, 6. [Epub ahead of print].
35. Zhu J.Z., Yu C.H., Li Y.M. Betatrophin provides a new insight into diabetes treatment and lipid metabolism (review). Biomed Rep 2014, 2:447-451.
36. Hu H., Sun W., Yu S., Hong X., Qian W., Tang B., et al. Increased circulating levels of betatrophin in newly diagnosed type 2 diabetic patients. Diabetes Care 2014, 37:2718-2722.
37. Espes D., Martinell M., Carlsson P.O. Increased circulating betatrophin concentrations in patients with type 2 diabetes. Int J Endocrinol 2014, 2014:323407.
38. Chen X., Lu P., He W., Zhang J., Liu L., Yang Y., et al. Circulating betatrophin levels are increased in patients with type 2 diabetes and associated with insulin resistance. J Clin Endocrinol Metab 2015, 100:E96-E100.
39. Fu Z., Abou-Samra A.B., Zhang R. An explanation for recent discrepancies in levels of human circulating betatrophin. Diabetologia 2014, 57:2232-2234.
40. Kugelberg E. Diabetes: betatrophin-inducing beta cell expansion to treat diabetes mellitus?. Nat Rev Endocrinol 2013, 9:379.
41. Gusarova V., Alexa C.A., Na E., Stevis P.E., Xin Y., Bonner-Weir S., et al. ANGPTL8/betatrophin does not control pancreatic beta cell expansion. Cell 2014, 159:691-696.
42. Mezza T., Muscogiuri G., Sorice G.P., Clemente G., Hu J., Pontecorvi A., et al. Insulin resistance alters islet morphology in nondiabetic humans. Diabetes 2014, 63:994-1007.
43. Assmann A., Hinault C., Kulkarni R.N. Growth factor control of pancreatic islet regeneration and function. Pediatr Diabetes 2009, 10:14-32.
44. Halperin F., Lopez X., Manning R., Kahn C.R., Kulkarni R.N., Goldfine A.B. Insulin augmentation of glucose-stimulated insulin secretion is impaired in insulin resistant humans. Diabetes 2012, 61:301-309.